Drugs · Entity Annotation Prototype (beta)

2articles mentioning drugs

2drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: lisocabtagene maraleucel ×

lisocabtagene maraleucel

This drug is selected. Its supporting articles are shown below.

lisocabtagene maraleucel2

Articles mentioning lisocabtagene maraleucel

2 articles · page 1 of 1

6ER-044 Evaluation of health and economic impacts of vein-to-vein time in the treatment of B-cell lymphoma with chimeric antigen receptor T-cell therapies: a systematic review

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

95.1%

Axicabtagene Ciloleucel tisagenlecleucel lisocabtagene maraleucel R/R LBCL Chimeric antigen receptor (CAR) T-cell therapies

…act of Vein-to-vein Time in Patients With R/R LBCL Treated with Axicabtagene Ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663–2676. doi: 10.1182/bloodadva…

1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles

jitc · abstract · 2025-11-04 · 1 matching annotations

96.0%

lisocabtagene maraleucel mosunetuzumab glofitamab axicabtagene ciloleucel BsAbs B-cell lymphomas FL follicular lymphoma LBCL relapsed/refractory B-cell lymphomas+2 more